Multimolecular characteristics of cell-death related hub genes in human cancers: a comprehensive pan-cancer analysis

References

• Fang Y, Tian S, Pan Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121:109595.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhong B, Xiao Q, et al. Induction of programmed necrosis: a novel anti-cancer strategy for natural compounds. Pharmacol Ther. 2020;214:107593.
   PubMed Web of Science ®Google Scholar
• Fulda S. Regulation of cell death in cancer-possible implications for immunotherapy. Front Oncol. 2013;3:29.
   PubMedGoogle Scholar
• D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–592.
   PubMed Web of Science ®Google Scholar
• Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245–254.
   PubMed Web of Science ®Google Scholar
• Fernandes-Alnemri T, Wu J, Yu JW, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14(9):1590–1604.
   PubMed Web of Science ®Google Scholar
• Cerella C, Teiten MH, Radogna F, et al. From nature to bedside: pro-survival and cell death mechanisms as therapeutic targets in cancer treatment. Biotechnol Adv. 2014;32(6):1111–1122.
   PubMed Web of Science ®Google Scholar
• Kerr JF, Searle J. A mode of cell loss in malignant neoplasms. J Pathol. 1972;106(1): Pxi.
   Google Scholar
• Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1069–1075.
   PubMed Web of Science ®Google Scholar
• Nixon RA, Yang DS. Autophagy failure in Alzheimer’s disease–locating the primary defect. Neurobiol Dis. 2011;43(1):38–45.
   PubMed Web of Science ®Google Scholar
• Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487–498.
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73(4):1907–1916.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77.
   PubMedGoogle Scholar
• Vivian J, Rao AA, Nothaft FA, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314–316.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
   Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. Timer: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110.
   PubMed Web of Science ®Google Scholar
• Angel P, Hattori K, Smeal T, et al. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell. 1988;55(5):875–885.
   PubMedGoogle Scholar
• Boettcher S, Miller PG, Sharma R, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365(6453):599–604.
   PubMed Web of Science ®Google Scholar
• Donoghue S, Baden HS, Lauder I, et al. Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma. Cancer Res. 1999;59(20):5386–5391.
   PubMedGoogle Scholar
• Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998;92(9):3090–3097.
   PubMedGoogle Scholar
• Faderl S, Thall PF, Kantarjian HM, et al. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999;5(12):4041–4047.
   PubMedGoogle Scholar
• Kaltschmidt B, Kaltschmidt C, Hofmann TG, et al. The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur J Biochem. 2000;267(12):3828–3835.
   PubMedGoogle Scholar
• Lee MH, Na H, Kim EJ, et al. Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1. Oncogene. 2012;31(49):5099–5107.
   PubMedGoogle Scholar
• Sun Y, Chen XY, Liu J, et al. Differential caspase-3 expression in noncancerous, premalignant and cancer tissues of stomach and its clinical implication. Cancer Detect Prev. 2006;30(2):168–173.
   PubMedGoogle Scholar
• Winter RN, Kramer A, Borkowski A, et al. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001;61(3):1227–1232.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li D, Huang D, et al. Risk-associated long noncoding RNA FOXD3-AS1 inhibits neuroblastoma progression by repressing PARP1-mediated activation of CTCF. Mol Ther. 2018;26(3):755–773.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714.
   PubMed Web of Science ®Google Scholar
• Basu S, Ma R, Mikulla B, et al. Apoptosis of human carcinoma cells in the presence of inhibitors of glycosphingolipid biosynthesis: i. treatment of colo-205 and SKBR3 cells with isomers of PDMP and PPMP. Glycoconj J. 2004;20(3):157–168.
   PubMed Web of Science ®Google Scholar
• Yoo J, Kim CH, Song SH, et al. Expression of caspase-3 and c-myc in non-small cell lung cancer. Cancer Res Treat. 2004;36:303–307.
   PubMedGoogle Scholar
• Okouoyo S, Herzer K, Ucur E, et al. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer. 2004;108:580–587.
   PubMed Web of Science ®Google Scholar
• Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol. 2010;2(3):a1016.
   Google Scholar
• Pettitt SJ, Krastev DB, Brandsma I, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018;9:1849.
   PubMed Web of Science ®Google Scholar
• Voce DJ, Schmitt AM, Uppal A, et al. Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor. Oncogene. 2015;34:2807–2813.
   PubMedGoogle Scholar
• Soung YH, Lee JW, Kim SY, et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet. 2004;115:112–115.
   PubMed Web of Science ®Google Scholar
• Lukey MJ, Greene KS, Erickson JW, et al. The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. Nat Commun. 2016;7:11321.
   PubMed Web of Science ®Google Scholar
• Anteneh H, Fang J, Song J. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation. Nat Commun. 2020;11:2294.
   PubMedGoogle Scholar
• Van Baak TE, Coarfa C, Dugue PA, et al. Epigenetic supersimilarity of monozygotic twin pairs. Genome Biol. 2018;19:2.
   PubMed Web of Science ®Google Scholar
• Weiss EM, Wunderlich R, Ebel N, et al. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol. 2012;2:132.
   PubMedGoogle Scholar
• Kalafati L, Kourtzelis I, Schulte-Schrepping J, et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183:771–785.
   PubMed Web of Science ®Google Scholar
• Shao N, Tang H, Mi Y, et al. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. Oncoimmunology. 2020;9:1762473.
   PubMedGoogle Scholar
• Efstathiou JA, Mouw KW, Gibb EA, et al. Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer. Eur Urol. 2019;76:59–68.
   PubMed Web of Science ®Google Scholar
• Ali HR, Chlon L, Pharoah PD, et al. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. Plos Med. 2016;13:e1002194.
   PubMed Web of Science ®Google Scholar
• Prizment AE, Vierkant RA, Smyrk TC, et al. Cytotoxic T cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev. 2017;26:622–631.
   PubMed Web of Science ®Google Scholar
• Kim CG, Ahn JB, Jung M, et al. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016;115:25–33.
   PubMed Web of Science ®Google Scholar
• An C, Choi IS, Yao JC, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005;11:656–663.
   PubMed Web of Science ®Google Scholar
• Lee DW, Han SW, Bae JM, et al. Tumor mutation burden and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin. Clin Cancer Res. 2019;25:6141–6147.
   PubMedGoogle Scholar
• Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–133.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
   PubMed Web of Science ®Google Scholar
• Sato H, Jeggo PA, Shibata A. Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: implications for precision medicine. Cancer Sci. 2019;110:3415–3423.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
   PubMed Web of Science ®Google Scholar